Oral Treatment of Hemophilia


One of the challenges in treating hemophilia is that patients frequently develop antibodies to the protein(s) used to correct clotting factor deficiencies. This patented technology is a method for oral administration of a clotting factor to induce immunologic tolerance while providing therapeutic levels of clotting factor replacement.  The method can be a stand-alone treatment, or can be used in combination with other treatments.

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Oral Treatment of Hemophilia US 371 Utility *United States 10/485,696 7,220,718 2/2/2004 5/22/2007 8/3/2021 Issued
Oral Treatment of Hemophilia US Divisional *United States 11/734,489 7,867,974 4/12/2007 1/11/2011 9/27/2023 Issued
Drug Delivery
For Information, Contact:
Rob Whitehead
Senior Licensing Manager
Virginia Tech Intellectual Properties, Inc.
(540) 443-9219
William Velander
Oral Alpan
Tirumalaj Kamala
Polly Matzinger
Pharmaceuticals & Biotechnology
© 2020. All Rights Reserved. Powered by Inteum